Published in Indian J Exp Biol on June 01, 2009
Novel arylimidamides for treatment of visceral leishmaniasis. Antimicrob Agents Chemother (2010) 1.45
Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? Int J Parasitol Drugs Drug Resist (2012) 1.20
A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line. J Vis Exp (2012) 1.12
Visceral leishmaniasis: experimental models for drug discovery. Indian J Med Res (2011) 1.12
Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay. Antimicrob Agents Chemother (2013) 1.06
Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis. Chem Rev (2014) 1.00
A novel Leishmania major amastigote assay in 96-well format for rapid drug screening and its use for discovery and evaluation of a new class of leishmanicidal quinolinium salts. Antimicrob Agents Chemother (2013) 0.91
A unique modification of the eukaryotic initiation factor 5A shows the presence of the complete hypusine pathway in Leishmania donovani. PLoS One (2012) 0.84
A Review: The Current In Vivo Models for the Discovery and Utility of New Anti-leishmanial Drugs Targeting Cutaneous Leishmaniasis. PLoS Negl Trop Dis (2015) 0.83
Antileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box Against Intracellular Leishmania major Amastigotes. Am J Trop Med Hyg (2015) 0.79
The genome of the kinetoplastid parasite, Leishmania major. Science (2005) 8.64
Leishmaniasis. Lancet (1999) 7.20
The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg (2001) 6.02
Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis (2000) 3.72
Post-kala-azar dermal leishmaniasis. Lancet Infect Dis (2003) 3.63
Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase. Antimicrob Agents Chemother (1996) 3.62
Epidemiology of visceral leishmaniasis in India. Natl Med J India (1999) 2.37
Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Mol Biochem Parasitol (2000) 2.10
Post kala-azar dermal leishmaniasis: a neglected aspect of kala-azar control programmes. Ann Trop Med Parasitol (1992) 1.56
Role of ABC transporter MRPA, gamma-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani. J Antimicrob Chemother (2007) 1.38
Leishmania-HIV interaction: immunopathogenic mechanisms. Parasitol Today (1999) 1.31
Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis (2000) 1.29
Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India. Indian J Med Res (2008) 1.25
Colorimetric assay for screening compounds against Leishmania amastigotes grown in macrophages. Am J Trop Med Hyg (2005) 1.21
Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg (2000) 1.15
In vitro evaluation of CENTA, a new beta-lactamase-susceptible chromogenic cephalosporin reagent. J Clin Microbiol (1982) 1.01
Treatment of visceral leishmaniasis. Med Microbiol Immunol (2001) 0.94
Leishmania amastigotes as targets for drug screening. Kinetoplastid Biol Dis (2006) 0.86
Kala-azar--new developments in diagnosis and treatment. Indian J Pediatr (2000) 0.83
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis (2010) 3.71
Genome-wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis. Cell (2010) 2.91
Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov (2008) 2.58
Molecular and morphological heterogeneity of neural precursors in the mouse neocortical proliferative zones. J Neurosci (2006) 2.49
Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. Mol Biochem Parasitol (2006) 2.45
Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. Nat Struct Mol Biol (2010) 2.34
Vitamin D levels in Indian children with intrathoracic tuberculosis. Indian J Med Res (2014) 2.07
Non-tuberculous mycobacteria in TB-endemic countries: are we neglecting the danger? PLoS Negl Trop Dis (2010) 2.03
Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice. J Med Chem (2009) 1.87
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem (2005) 1.81
Rational modification of a candidate cancer drug for use against Chagas disease. J Med Chem (2009) 1.73
Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med (2013) 1.69
Retracted Insect vectors of Leishmania: distribution, physiology and their control. J Vector Borne Dis (2008) 1.67
Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem (2007) 1.62
Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. Mol Biochem Parasitol (2003) 1.61
Urine as an adjunct specimen for the diagnosis of active pulmonary tuberculosis. Int J Infect Dis (2008) 1.61
The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem (2005) 1.60
Second generation tetrahydroquinoline-based protein farnesyltransferase inhibitors as antimalarials. J Med Chem (2007) 1.60
Assessment of the N-PCR assay in diagnosis of pleural tuberculosis: detection of M. tuberculosis in pleural fluid and sputum collected in tandem. PLoS One (2010) 1.46
A novel copper chelate modulates tumor associated macrophages to promote anti-tumor response of T cells. PLoS One (2009) 1.45
Visceral leishmaniasis - current therapeutic modalities. Indian J Med Res (2006) 1.45
Novel arylimidamides for treatment of visceral leishmaniasis. Antimicrob Agents Chemother (2010) 1.45
Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother (2007) 1.43
Role of ABC transporter MRPA, gamma-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani. J Antimicrob Chemother (2007) 1.38
Selective inhibitors of methionyl-tRNA synthetase have potent activity against Trypanosoma brucei Infection in Mice. Antimicrob Agents Chemother (2011) 1.37
Thematic review series: lipid posttranslational modifications. Fighting parasitic disease by blocking protein farnesylation. J Lipid Res (2005) 1.36
Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: selectivity and in vivo characterization. J Med Chem (2012) 1.35
Development of a modified MTT assay for screening antimonial resistant field isolates of Indian visceral leishmaniasis. Parasitol Int (2005) 1.34
Hepatitis B and C virus co-infections in human immunodeficiency virus positive North Indian patients. World J Gastroenterol (2006) 1.33
Occult hepatitis B virus infection in ART-naive HIV-infected patients seen at a tertiary care centre in north India. BMC Infect Dis (2010) 1.32
Semen of HIV-1-infected individuals: local shedding of herpesviruses and reprogrammed cytokine network. J Infect Dis (2011) 1.29
Hepatitis B in health care workers: Indian scenario. J Lab Physicians (2009) 1.29
Heterologous expression of L. major proteins in S. cerevisiae: a test of solubility, purity, and gene recoding. J Struct Funct Genomics (2009) 1.28
Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. J Med Chem (2011) 1.28
Plant derived therapeutics for the treatment of Leishmaniasis. Phytomedicine (2011) 1.27
Artemisinin triggers induction of cell-cycle arrest and apoptosis in Leishmania donovani promastigotes. J Med Microbiol (2007) 1.27
Drug targets in Leishmania. J Parasit Dis (2010) 1.26
Buffer optimization of thermal melt assays of Plasmodium proteins for detection of small-molecule ligands. J Biomol Screen (2009) 1.25
Immunobiology of leishmaniasis. Indian J Exp Biol (2009) 1.23
Characterization of Trypanosoma brucei dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies. Mol Microbiol (2008) 1.22
Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob Agents Chemother (2008) 1.21
Structural genomics of pathogenic protozoa: an overview. Methods Mol Biol (2008) 1.20
Cloning, expression, and purification of a novel recombinant antigen from Leishmania donovani. Protein Expr Purif (2005) 1.19
Distinct states of methionyl-tRNA synthetase indicate inhibitor binding by conformational selection. Structure (2012) 1.18
Post-kala-azar dermal leishmaniasis--an overview. Int J Dermatol (2010) 1.15
Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and -resistant clinical isolates of Leishmania donovani from India. J Antimicrob Chemother (2010) 1.14
Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res (2010) 1.13
Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. J Med Chem (2010) 1.11
Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. J Med Chem (2009) 1.10
Cholesterol is required for Leishmania donovani infection: implications in leishmaniasis. Mol Biochem Parasitol (2004) 1.10
Paromomycin: uptake and resistance in Leishmania donovani. Mol Biochem Parasitol (2008) 1.10
Oxidative stress as a potential biomarker for determining disease activity in patients with rheumatoid arthritis. Free Radic Res (2012) 1.09
Roles for mitochondria in pentamidine susceptibility and resistance in Leishmania donovani. Mol Biochem Parasitol (2005) 1.08
Molecular characterization of Mycobacterium tuberculosis isolates from North Indian patients with extrapulmonary tuberculosis. Tuberculosis (Edinb) (2012) 1.07
Expression and characterization of a recombinant kinesin antigen from an old Indian strain (DD8) of Leishmania donovani and comparing it with a commercially available antigen from a newly isolated (KE16) strain of L. donovani. Infect Genet Evol (2008) 1.07
Leishmania major activates IL-1 alpha expression in macrophages through a MyD88-dependent pathway. Microbes Infect (2002) 1.07
Seroprevalence of toxoplasma infection among primigravid women attending antenatal clinic at a secondary level hospital in North India. J Indian Med Assoc (2002) 1.06
Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis. J Infect Dis (2008) 1.06
Elevated levels of tryparedoxin peroxidase in antimony unresponsive Leishmania donovani field isolates. Mol Biochem Parasitol (2010) 1.05
Chronic arsenic exposure impairs macrophage functions in the exposed individuals. J Clin Immunol (2009) 1.03
Seroprevalence of HIV in pregnant women in North India: a tertiary care hospital based study. BMC Infect Dis (2007) 1.03
Mycobacterium tuberculosis evades host immunity by recruiting mesenchymal stem cells. Proc Natl Acad Sci U S A (2010) 1.02
Functionality of drug efflux pumps in antimonial resistant Leishmania donovani field isolates. Indian J Biochem Biophys (2009) 1.02
Recovery of Mycobacterium tuberculosis from sputum treated with cetyl pyridinium chloride. J Clin Microbiol (2009) 1.02
Intracellular GSH depletion triggered mitochondrial Bax translocation to accomplish resveratrol-induced apoptosis in the U937 cell line. J Pharmacol Exp Ther (2010) 1.02
Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis. Chem Rev (2014) 1.00
Using fragment cocktail crystallography to assist inhibitor design of Trypanosoma brucei nucleoside 2-deoxyribosyltransferase. J Med Chem (2006) 1.00
Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis. J Infect Dis (2011) 0.99
Structure of a Trypanosoma brucei alpha/beta-hydrolase fold protein with unknown function. Acta Crystallogr Sect F Struct Biol Cryst Commun (2008) 0.99
Structures of substrate- and inhibitor-bound adenosine deaminase from a human malaria parasite show a dramatic conformational change and shed light on drug selectivity. J Mol Biol (2008) 0.98
Leishmania-HIV co-infection: an emerging problem in India. AIDS (2006) 0.98
Crystal structures of trypanosomal histidyl-tRNA synthetase illuminate differences between eukaryotic and prokaryotic homologs. J Mol Biol (2010) 0.97
Commercial serological tests for the diagnosis of active tuberculosis in India: time for introspection. Indian J Med Res (2011) 0.97
Incidence and prevalence of tuberculosis among household contacts of pulmonary tuberculosis patients in a peri-urban population of South Delhi, India. PLoS One (2013) 0.97
An ethanolic extract of leaves of Piper betle (Paan) Linn mediates its antileishmanial activity via apoptosis. Parasitol Res (2008) 0.97
Food crisis and AIDS: the Indian perspective. Lancet (2003) 0.96
Role of horizontal transmission in hepatitis B virus spread among household contacts in north India. Intervirology (2008) 0.96
Substituted 2-phenylimidazopyridines: a new class of drug leads for human African trypanosomiasis. J Med Chem (2014) 0.96
Antibiotic susceptibilities, streptococcal pyrogenic exotoxin gene profiles among clinical isolates of group C or G Streptococcus dysgalactiae subsp. equisimilis & of group G S. anginosus group at a tertiary care centre. Indian J Med Res (2014) 0.95
Effect of Mycobacterium tuberculosis-specific 10-kilodalton antigen on macrophage release of tumor necrosis factor alpha and nitric oxide. Infect Immun (2002) 0.95
Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. J Med Chem (2006) 0.95
A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis. J Infect Dis (2005) 0.95
Aloe vera leaf exudate induces a caspase-independent cell death in Leishmania donovani promastigotes. J Med Microbiol (2007) 0.95
In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability. Bioorg Med Chem (2004) 0.95
Development of a semi-automated colorimetric assay for screening anti-leishmanial agents. J Microbiol Methods (2005) 0.95
In-vitro antimycobacterial drug susceptibility testing of non-tubercular mycobacteria by tetrazolium microplate assay. Ann Clin Microbiol Antimicrob (2008) 0.94
In vitro antileishmanial activity of Aloe vera leaf exudate: a potential herbal therapy in leishmaniasis. Glycoconj J (2007) 0.93
Structure of Leishmania major methionyl-tRNA synthetase in complex with intermediate products methionyladenylate and pyrophosphate. Biochimie (2010) 0.93
Variable degree of alternative complement pathway-mediated hemolysis in Indian visceral leishmaniasis induced by differential expression of 9-O-acetylated sialoglycans. J Infect Dis (2004) 0.93
Anti-inflammatory effect of allylpyrocatechol in LPS-induced macrophages is mediated by suppression of iNOS and COX-2 via the NF-kappaB pathway. Int Immunopharmacol (2008) 0.93
Variable-number tandem repeat 3690 polymorphism in Indian clinical isolates of Mycobacterium tuberculosis and its influence on transcription. J Med Microbiol (2009) 0.92
Role of aquaglyceroporin (AQP1) gene and drug uptake in antimony-resistant clinical isolates of Leishmania donovani. Am J Trop Med Hyg (2008) 0.92